A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

NCT05678270 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Intrahepatic Cholangiocarcinoma (ICC)

Interventions

DRUG: ICP-192

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.